Stratos Wealth Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Stratos Wealth Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$579K	Sell	7,715 -25	-0.3%	-$1.97K	0.01%	1012
2025 Q4	$612K	Sell	7,740 -24	-0.3%	-$1.81K	0.01%	959
2025 Q3	$508K	Buy	+7,764	New	+$379K	0.01%	1010
2025 Q1	–	Sell	-12,813	Closed	-$448K	–	1440
2024 Q4	$448K	Buy	12,813 +25	+0.2%	+$934	0.01%	982
2024 Q3	$512K	Sell	12,788 -3	-0%	-$140	0.01%	936
2024 Q2	$610K	Buy	+12,791	New	+$525K	0.01%	829
2020 Q3	–	Sell	-4,296	Closed	-$253K	–	1034
2020 Q2	$253K	Sell	4,296 -456	-10%	-$25.4K	0.01%	822
2020 Q1	$225K	Buy	+4,752	New	+$265K	0.01%	773
2018 Q4	–	Sell	-862	Closed	-$44K	–	1631
2018 Q3	$44K	Buy	+862	New	+$40.5K	﹤0.01%	1513
2018 Q2	–	Sell	-1,611	Closed	-$71K	–	1754
2018 Q1	$71K	Sell	1,611 -482	-23%	-$24.5K	﹤0.01%	1384
2017 Q4	$105K	Buy	+2,093	New	+$115K	﹤0.01%	1167

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stratos Wealth Partners's IONS Position: Q1 2026 in Review

Stratos Wealth Partners reduced its Ionis Pharmaceuticals (IONS) stake by 0.32% in Q1 2026, selling an estimated $1.97K and leaving 7,715 shares worth $579K. The position accounts for 0.01% of the portfolio, ranked #1012.

Stratos Wealth Partners first reported a position in IONS in Q4 2017 and has held it in 11 quarters since. The position peaked at $612K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Stratos Wealth Partners held 7,715 shares of Ionis Pharmaceuticals worth $579K as of Q1 2026.
Stratos Wealth Partners sold 25 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.97K.
Ionis Pharmaceuticals made up 0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1012 holding.
Stratos Wealth Partners first reported a position in Ionis Pharmaceuticals in Q4 2017 and has held it in 11 quarters since.
Stratos Wealth Partners's Ionis Pharmaceuticals position peaked at $612K in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.